Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) saw a large growth in short interest in September. As of September 14th, there was short interest totalling 1,073,600 shares, a growth of 1.1% from the August 31st total of 1,061,697 shares. Based on an average daily volume of 102,364 shares, the short-interest ratio is currently 10.5 days. Approximately 6.9% of the shares of the stock are sold short.

Separately, HC Wainwright set a $6.00 target price on shares of Ampliphi Biosciences and gave the stock a “buy” rating in a research report on Friday, August 10th.

Ampliphi Biosciences stock opened at $1.02 on Friday. Ampliphi Biosciences has a 52 week low of $0.76 and a 52 week high of $2.05.

Ampliphi Biosciences (NYSEAMERICAN:APHB) last released its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.01. Ampliphi Biosciences had a negative net margin of 2,050.00% and a negative return on equity of 31.85%.

An institutional investor recently bought a new position in Ampliphi Biosciences stock. Sabby Management LLC acquired a new position in Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) during the 1st quarter, according to its most recent filing with the SEC. The fund acquired 831,961 shares of the biotechnology company’s stock, valued at approximately $907,000. Sabby Management LLC owned approximately 5.05% of Ampliphi Biosciences as of its most recent SEC filing.

Ampliphi Biosciences Company Profile

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus infections; and AB-PA01 for the treatment of pseudomonas aeruginosa infections.

Featured Article: How can investors find ex-dividend dates?

Receive News & Ratings for Ampliphi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences and related companies with's FREE daily email newsletter.